Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma

Cancer Immunology, Immunotherapy

Volumn 64, Issue 3, 2015, Pages 349-355

  Køstner, Anne Helene ^a   Ellegaard, Mai Britt Bjørklund ^a   Christensen, Ib Jarle ^b   Bastholt, Lars ^c   Schmidt, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Fever; IL 2; Immunotherapy; Interferon; Melanoma

Indexed keywords

INTERLEUKIN 2; LACTATE DEHYDROGENASE; PARACETAMOL; PEGINTERFERON; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY TEMPERATURE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; FEMALE; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; CHEMICALLY INDUCED; FEVER; IMMUNOTHERAPY; MELANOMA; MIDDLE AGED; PROCEDURES; PROGNOSIS; YOUNG ADULT;

ACETAMINOPHEN; ADOLESCENT; ADULT; AGED; ANALGESICS, NON-NARCOTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; FEVER; HUMANS; IMMUNOTHERAPY; INTERFERONS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84925495986     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1637-5     Document Type: Article

References (28)

1. Diepgen TL, Mahler V (2002) The epidemiology of skin cancer. Br J Dermatol 146(Suppl 61):1–6
2. Volkovova K, Bilanicova D, Bartonova A, Letasiova S, Dusinska M (2012) Associations between environmental factors and incidence of cutaneous melanoma. Review. Environ Health 11(Suppl 1):S12. doi:10.1186/1476-069x-11-s1-s12
3. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi:10.1056/NEJMoa1003466
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516. doi:10.1056/NEJMoa1103782
5. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. doi:10.1056/NEJMoa1200690
6. Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23(6):488–496
7. Antony GK, Dudek AZ (2010) Interleukin 2 in cancer therapy. Curr Med Chem 17(29):3297–3302
8. Hasday JD, Fairchild KD, Shanholtz C (2000) The role of fever in the infected host. Microbes infect 2(15):1891–1904
9. Hobohm U (2005) Fever therapy revisited. Br J Cancer 92(3):421–425. doi:10.1038/sj.bjc.6602386
10. Kleef R, Jonas WB, Knogler W, Stenzinger W (2001) Fever, cancer incidence and spontaneous remissions. Neuroimmunomodulation 9(2):55–64. doi:10.1159/000049008
11. Kluger MJ (1986) Is fever beneficial? Yale J Biol Med 59(2):89–95
12. Roberts NJ Jr (1991) Impact of temperature elevation on immunologic defenses. Rev Infect Dis 13(3):462–472
13. Basu S, Srivastava PK (2003) Fever-like temperature induces maturation of dendritic cells through induction of hsp90. Int Immunol 15(9):1053–1061
14. Hobohm U, Stanford JL, Grange JM (2008) Pathogen-associated molecular pattern in cancer immunotherapy. Crit Rev Immunol 28(2):95–107
15. Mace TA, Zhong L, Kokolus KM, Repasky EA (2012) Effector CD8+ T cell IFN-gamma production and cytotoxicity are enhanced by mild hyperthermia. Int J Hyperth 28(1):9–18. doi:10.3109/02656736.2011.616182
16. Ostberg JR, Repasky EA (2006) Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function. Cancer Immunol Immunother 55(3):292–298. doi:10.1007/s00262-005-0689-y
17. Jozwiak-Bebenista M, Nowak JZ (2014) Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm 71(1):11–23
18. Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U (2007) Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 25(12):1562–1569. doi:10.1200/jco.2006.09.0274
19. Wisco OJ, Sober AJ (2012) Prognostic factors for melanoma. Dermatol Clin 30(3):469–485. doi:10.1016/j.det.2012.04.008
20. Mier JW, Vachino G, Klempner MS, Aronson FR, Noring R, Smith S, Brandon EP, Laird W, Atkins MB (1990) Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 76(10):1933–1940
21. Mier JW, Vachino G, van der Meer JW, Numerof RP, Adams S, Cannon JG, Bernheim HA, Atkins MB, Parkinson DR, Dinarello CA (1988) Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 8(6):426–436
22. Roberts NJ, Zhou S, Diaz LA Jr, Holdhoff M (2011) Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2(10):739–751
23. Hobohm U (2001) Fever and cancer in perspective. Cancer Immunol Immunother 50(8):391–396
24. Eberlein TJ, Schoof DD, Michie HR, Massaro AF, Burger U, Wilmore DW, Wilson RE (1989) Ibuprofen causes reduced toxic effects of interleukin 2 administration in patients with metastatic cancer. Arch Surg 124(5):542–547
25. Sosman JA, Kohler PC, Hank JA, Moore KH, Bechhofer R, Storer B, Sondel PM (1988) Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 80(18):1451–1461
26. Hoption Cann SA, van Netten JP, van Netten C (2003) Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 79(938):672–680
27. Nauts HC, Fowler GA, Bogatko FH (1953) A review of the influence of bacterial infection and of bacterial products (Coley’s toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley’s mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl 276:1–103
28. Hoption Cann SA, van Netten JP, van Netten C, Glover DW (2002) Spontaneous regression: a hidden treasure buried in time. Med Hypotheses 58(2):115–119. doi:10.1054/mehy.2001.1469